BCRX Financial Facts

Research and development: 13.04M
Collaborative and other research and development: 3.23M
See Full Income Statement

Total current assets: 135.14M
Deferred collaboration revenue: 1.48M
See Full Balance Sheet

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings

  |   Expand Research on BCRX
Next EPS Date 8/5/15 *Est. EPS Growth Rate -23.5% *Last Qtr.
Average EPS % Beat Rate +14.7% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +3.4% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/8/15 Q115 -$0.21-$0.25 +$0.04$6.8M$4.3M N/A Details
2/18/15 Q414 -$0.16-$0.21 +$0.05$5.4M$3.64M N/A Details
11/6/14 Q314 -$0.12-$0.20 +$0.08$3.2M$2.11M N/A Details
8/5/14 Q214 -$0.23-$0.19 -$0.04$1.5M$2.32M N/A Details
5/8/14 Q114 -$0.17-$0.17 $0.00N/A$3.34M N/A Details
2/26/14 Q413 -$0.09-$0.08 -$0.01$10.6M$8.81M N/A Details
11/5/13 Q313 -$0.14-$0.14 $0.00$2.4M$2.01M N/A Details
8/8/13 Q213 -$0.23-$0.14 -$0.09$821K$2.01M N/A Details